Send to

Choose Destination
Diabetes Ther. 2015 Sep;6(3):239-56. doi: 10.1007/s13300-015-0127-x. Epub 2015 Aug 14.

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.

Author information

University of Milan, Milan, Italy.
Diabetes Endocrine and Metabolic Diseases Unit, IRCCS MultiMedica, 20099, Sesto San Giovanni, MI, Italy.
Diabetes Agency, Careggi Hospital, Florence, Italy.
Insititut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain.


Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.


GLP-1 RAs; Glucagon-like peptide-1 receptor agonists; Incretin; Type 2 diabetes mellitus

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center